|Articles|April 10, 2018
The Benefits of Jakafi for Patients With PV
Author(s)Jeanne M. Palmer, M.D.
Patients with PV tend to be very symptomatic, but Jakafi can help.
Advertisement
Jeanne M. Palmer, M.D., hematologist oncologist at the Mayo Clinic in Arizona discusses the benefit of Jakafi (ruxolitinib) for patients with polycythemia vera (PV) — a type of myeloproliferative neoplasm.
Patients with PV tend to be very symptomatic, and Jakafi provides good symptom control compared to some other PV treatments that have their own set of risks and side effects.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Blood Test May Predict Imdelltra Benefit in Small Cell Lung Cancer
2
Active Lifestyle Changes Following an MDS Diagnosis
3
Cancer Vaccine Plus Keytruda Reduces Melanoma Recurrence or Death
4
How A Cancer Vaccine and Keytruda Work to Treat Patients With Melanoma
5